|
Market Closed -
London S.E.
11:35:19 2026-10-07 am EDT
|
5-day change | 1st Jan Change | ||
| 1,790.50 GBX | +1.42% |
|
-2.27% | -1.86% |
| Oct. 07 | The Rally Is Getting Lonely |  |
| Oct. 07 | GSK plc : Berenberg remains its Buy rating | ZD |
| Market Cap | 71.75B 94.81B 84.61B 78.97B 135B 9,170B 136B 948B 370B 4,665B 356B 348B 14,980B | P/E 2026 * |
13.9x | P/E 2027 * | 11.4x |
|---|---|---|---|---|---|
| Enterprise Value | 92.96B 123B 110B 102B 175B 11,881B 176B 1,228B 479B 6,044B 461B 451B 19,408B | EV / Sales 2026 * |
2.74x | EV / Sales 2027 * | 2.54x |
| Free-Float |
92.75% | Yield 2026 * |
3.88% | Yield 2027 * | 4.18% |
| Markets | Quality | ||
|---|---|---|---|
London S.E.
| GSK | Delayed | |
CBOE
| GSK | Real-time | |
|
Xetra
| GS71 | Delayed | |
|
OTC Markets
| GLAXF | Delayed | |
|
Tradegate
| GS71 | Real-time | |
|
Boerse Muenchen
| GS71 | Real-time | |
|
Börse Stuttgart
| GS71 | Delayed | |
|
Mexican S.E.
| GSK1 N | End-of-day quote | |
|
Deutsche Boerse AG
| GS71 | Delayed |
Last Transcript: GSK plc
| Oct. 07 | GSK plc : Berenberg remains its Buy rating | ZD |
| Oct. 01 | GSK plc : JP Morgan reiterates its Sell rating | ZD |
| Sep. 29 | GSK plc : Gets a Neutral rating from Deutsche Bank | ZD |
| Sep. 29 | GSK plc : Jefferies keeps its Buy rating | ZD |
| Sep. 18 | GSK plc : Deutsche Bank remains Neutral | ZD |
| 1 day | +1.42% | ||
| 1 week | -2.27% | ||
| Current month | -2.27% | ||
| 1 month | -2.56% | ||
| 3 months | -10.61% | ||
| 6 months | -14.58% | ||
| Current year | -1.86% |
| 1 week | 1,740.5 |  | 1,832.18 |
| 1 month | 1,740.5 | | 1,917 |
| Current year | 1,690 | | 2,282 |
| 1 year | 1,592 | | 2,282 |
| 3 years | 1,242.5 | | 2,282 |
| 5 years | 1,242.5 | | 3,408.16 |
| 10 years | 1,242.5 | | 3,408.16 |
| Manager | Title | Age | Since |
|---|---|---|---|
Luke Miels
CEO | Chief Executive Officer | 52 | 2025-12-31 |
Julie Brown
DFI | Director of Finance/CFO | 64 | 2023-04-30 |
James Ford
CMP | Compliance Officer | - | 2018-07-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Luke Miels
BRD | Director/Board Member | 52 | 2026-05-05 |
Hal Barron
BRD | Director/Board Member | 64 | 2017-12-31 |
Jonathan Symonds
CHM | Chairman | 67 | 2019-08-31 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 9/22/26 | Buy | Executive/Senior Manager | 9 | 0.0000% | ||
| 9/18/26 | Buy | Director | 768 | 0.0000% | ||
| 9/18/26 | Buy | Director | 1,734 | 0.0000% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.42% | -2.27% | +10.90% | +18.72% | 93.95B | |
| +2.70% | +0.35% | +40.67% | +110.31% | 1,032B | |
| +1.44% | -3.41% | +37.36% | +63.95% | 614B | |
| +1.75% | +3.07% | +17.89% | +83.05% | 471B | |
| +0.60% | -4.35% | +60.80% | +37.46% | 350B | |
| +2.92% | +3.06% | +24.83% | +45.10% | 337B | |
| +2.42% | -0.74% | +13.44% | +35.80% | 268B | |
| +1.86% | -0.81% | -4.69% | +12.20% | 246B | |
| +2.60% | -2.49% | +40.45% | +54.44% | 218B | |
| +1.82% | -2.93% | +29.29% | +96.48% | 179B | |
| Average | +1.25% | -3.54% | +27.09% | +55.75% | 380.88B | |
| Weighted average by Cap. | +0.75% | -3.23% | +31.63% | +69.31% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 33.93B 44.83B 40.01B 37.34B 63.89B 4,336B 64.36B 448B 175B 2,206B 168B 165B 7,083B | 35.53B 46.95B 41.9B 39.11B 66.91B 4,542B 67.41B 469B 183B 2,310B 176B 172B 7,419B |
| Net income | 5.19B 6.86B 6.12B 5.71B 9.77B 663B 9.85B 68.55B 26.75B 337B 25.72B 25.18B 1,084B | 6.21B 8.21B 7.33B 6.84B 11.7B 794B 11.79B 82.06B 32.02B 404B 30.79B 30.14B 1,297B |
| Net Debt | 21.21B 28.03B 25.01B 23.35B 39.94B 2,711B 40.24B 280B 109B 1,379B 105B 103B 4,429B | 18.49B 24.44B 21.81B 20.35B 34.83B 2,364B 35.08B 244B 95.32B 1,202B 91.66B 89.74B 3,861B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-07 | GBX 1,790.50 | +1.42% | 5,065,808 |
| 26-10-06 | GBX 1,765.50 | +0.37% | 5,019,288 |
| 26-10-05 | GBX 1,759.00 | -1.15% | 3,780,146 |
| 26-10-02 | GBX 1,779.50 | -0.86% | 5,630,618 |
| 26-10-01 | GBX 1,795.00 | -2.02% | 8,593,783 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GSK Stock
Select your edition
All financial news and data tailored to specific country editions
